JP2024534602A5 - - Google Patents

Info

Publication number
JP2024534602A5
JP2024534602A5 JP2024518659A JP2024518659A JP2024534602A5 JP 2024534602 A5 JP2024534602 A5 JP 2024534602A5 JP 2024518659 A JP2024518659 A JP 2024518659A JP 2024518659 A JP2024518659 A JP 2024518659A JP 2024534602 A5 JP2024534602 A5 JP 2024534602A5
Authority
JP
Japan
Application number
JP2024518659A
Other languages
Japanese (ja)
Other versions
JP2024534602A (ja
JPWO2023049694A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076694 external-priority patent/WO2023049694A1/en
Publication of JP2024534602A publication Critical patent/JP2024534602A/ja
Publication of JP2024534602A5 publication Critical patent/JP2024534602A5/ja
Publication of JPWO2023049694A5 publication Critical patent/JPWO2023049694A5/ja
Pending legal-status Critical Current

Links

JP2024518659A 2021-09-23 2022-09-20 多発性骨髄腫を処置する方法 Pending JP2024534602A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163247637P 2021-09-23 2021-09-23
US63/247,637 2021-09-23
PCT/US2022/076694 WO2023049694A1 (en) 2021-09-23 2022-09-20 Methods of treating multiple myeloma

Publications (3)

Publication Number Publication Date
JP2024534602A JP2024534602A (ja) 2024-09-20
JP2024534602A5 true JP2024534602A5 (https=) 2025-09-22
JPWO2023049694A5 JPWO2023049694A5 (https=) 2025-09-22

Family

ID=83996580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518659A Pending JP2024534602A (ja) 2021-09-23 2022-09-20 多発性骨髄腫を処置する方法

Country Status (6)

Country Link
US (1) US20240343819A1 (https=)
EP (1) EP4405393A1 (https=)
JP (1) JP2024534602A (https=)
CA (1) CA3232799A1 (https=)
TW (1) TW202327650A (https=)
WO (1) WO2023049694A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
WO2025117764A1 (en) * 2023-12-01 2025-06-05 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
BR112021020409A2 (pt) * 2019-04-10 2021-12-07 Glaxosmithkline Ip Dev Ltd Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase

Similar Documents

Publication Publication Date Title
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13159U (https=)
BY13135U (https=)
BY13137U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13149U (https=)
BY13150U (https=)